Integra LifeSciences
IART
284 hedge funds and large institutions have $3.14B invested in Integra LifeSciences in 2023 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 87 increasing their positions, 105 reducing their positions, and 25 closing their positions.
104% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 25
85% more call options, than puts
Call options by funds: $548K | Put options by funds: $296K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
20% more capital invested
Capital invested by funds: $2.63B → $3.14B (+$517M)
8% more funds holding
Funds holding: 262 → 284 (+22)
8.04% more ownership
Funds ownership: 84.33% → 92.36% (+8%)
17% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$181M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$48.4M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$10.4M |
| 4 |
PE
Point72 Europe
London,
United Kingdom
|
+$10M |
| 5 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
+$9.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$57.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$23.5M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$22.7M |
| 4 |
ClearBridge Investments
New York
|
-$10.5M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$8.54M |
IART Hedge Fund Activity: Q4 2023 in Review
284 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2023, worth a combined $3.14B — up 20% from $2.63B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IART positions and 25 closed out — a net gain of 26 holders — while 87 added to existing stakes and 105 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $181M. The largest seller was Victory Capital Management, cutting an estimated $57.1M.
- 284 institutional investors held Integra LifeSciences (IART) as of Q4 2023, up from 262 in Q3 2023.
- Funds reported $3.14B of Integra LifeSciences stock for Q4 2023, up 20% quarter-over-quarter.
- 51 funds opened new Integra LifeSciences positions in Q4 2023 and 25 closed out, a net change of +26 holders.
- The largest Integra LifeSciences buyer in Q4 2023 was Morgan Stanley, an estimated $181M added.
- The largest Integra LifeSciences seller in Q4 2023 was Victory Capital Management, an estimated $57.1M sold.
Based on aggregated 13F filings for Q4 2023.